Abstract
The hippocampus is a vulnerable and plastic brain structure that is damaged by a variety of stimuli, e.g. hypoxia, hypoperfusion, hypoglycaemia, stress and seizures. Alzheimer’s disease is a common and important disorder in which hippocampal atrophy is reported. Indeed, the available evidence suggests that hippocampal atrophy is the starting point of the pathogenesis of Alzheimer’s disease and a significant number of patients with hippocampal atrophy will develop Alzheimer’s disease. Studies indicate that hippocampal atrophy has functional consequences, e.g. cognitive impairment. Deposition of tau protein, formation of neurofibrillary tangles and accumulation of β-amyloid (Aβ) contributes to hippocampal atrophy together with damage caused by several other factors. Some of the factors associated with the development of hippocampal atrophy in Alzheimer’s disease have been identified, e.g. hypertension, diabetes mellitus, hyperlipidaemia, seizures, affective disturbances and stress, and more is being learnt about other factors.
Hypertension can potentially damage the hippocampus through ischaemia caused by atherosclerosis and cerebral amyloid angiopathy. Diabetes can produce hippocampal lesions via both vascular and non-vascular pathologies and can reduce the threshold for hippocampal damage. Carriers of the apolipoprotein E (ApoE)-ɛ4 genotype have been shown to have greater mesial temporal atrophy and poorer memory functions than non-carriers. In addition to giving rise to abnormal lipid metabolism, the ApoE-ε4 allele can affect the course of Alzheimer’s disease via both Aβ-dependent and -independent pathways. Repetitive seizures can increase Aβ-peptide production and cause neurotransmission dysfunction and cytoskeletal abnormalities or a combination of these. Affective disturbances and stress are proposed to increase corticosteroid-induced hippocampal damage in many different ways.
In the absence of any specific markers for predicting Alzheimer’s disease progression, it seems appropriate to learn more about the various predictors of hippocampal atrophy that determine the progression of Alzheimer’s disease from mild cognitive impairment (MCI), and then attempt to address these. It would be interesting to know to what extent these predictors play a role in the development of MCI or hasten the conversion of MCI to fullblown Alzheimer’s disease. Finally, it would be useful to know the extent to which these predictors can worsen or aggravate existing Alzheimer’s disease.
Of the clinically used drugs in Alzheimer’s disease, anticholinesterases have been shown to slow down the rate of progression of hippocampal atrophy. One study observed that the neuroprotective effect of these agents is possibly due to an anti-Aβ effect produced by cholinergic stimulation. Similarly, antihypertensive and antihyperglycaemic drugs (pioglitazone and insulin) have been shown to reduce the risk of Alzheimer’s disease or disease progression. Currently, there are no disease-modifying therapies available for Alzheimer’s disease. It has been suggested that for treatment to be most effective, the regimen must be started before significant downstream damage has occurred (i.e. before the clinical diagnosis of Alzheimer’s disease, at the stage of MCI or earlier). Since the hippocampus is a plastic structure and atrophy of this structure is closely related to the pathophysiology of Alzheimer’s disease, if we could control blood pressure, regulate blood sugar, treat behavioural and psychological symptoms, achieve satisfactory lipid lowering and maintain a seizure-free state in patients with Alzheimer’s disease, this may not only improve disease control but could also potentially affect the rate of disease progression.
Similar content being viewed by others
References
Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009; 11(2): 111–28
Reitz C, Brickman AM, Brown TR, et al. Linking hippocampal structure and function to memory performance in an aging population. Arch Neurol 2009 Nov; 66(11): 1385–92
O’Sullivan M, Ngo E, Viswanathan A, et al. Hippocampal volume is an independent predictor of cognitive performance in CADASIL. Neurobiol Aging 2009 Jun; 30(6): 890–7
Dhikav V, Anand K. Hippocampal atrophy may be a predictor of seizures in Alzheimer’s disease. Med Hypotheses 2007; 69(1): 234–5
Doraiswamy PM, Steffens DC, McQuoid DR. Statin use and hippocampal volumes in elderly subjects at risk for Alzheimer’s disease: a pilot observational study. Am J Alzheimers Dis Other Dement 2004 Sep–Oct; 19(5): 275–8
Hayashi T, Wada A, Uchida N, et al. Enlargement of the hippocampal angle: a new index of Alzheimer disease. Magn Reson Med Sci 2009; 8(1): 33–8
Mega MS, Small GW, Xu ML, et al. Hippocampal atrophy in persons with age-associated memory impairment: volumetry within a common space. Psychosom Med 2002 May–Jun; 64(3): 487–92
de Toledo-Morrell L, Goncharova I, Dickerson B, et al. From healthy aging to early Alzheimer’s disease: in vivo detection of entorhinal cortex atrophy. Ann N Y Acad Sci 2000 Jun; 911: 240–53
McEwen BS. Stress and aging hippocampus. Front Neuroendocrinol 1999; 20: 49–70
Jack Jr CR, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999 Apr 22; 52(7): 1397–403
Rountree SD, Waring SC, Chan WC, et al. Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia. Dement Geriatr Cogn Disord 2007; 24(6): 476–82
Chetelat G, Baron JC. Early diagnosis of Alzheimer’s disease: contribution of structural neuroimaging. Neuroimage 2003 Feb; 18(2): 525–41
Bottino CM, Castro CC, Gomes RL, et al. Volumetric MRI measurements can differentiate Alzheimer’s disease, mild cognitive impairment, and normal aging. Int Psychogeriatr 2002 Mar; 14(1): 59–72
Yavuz BB, Ariogul S, Cankurtaran M, et al. Hippocampal atrophy correlates with the severity of cognitive decline. Int Psychogeriatr 2007 Aug; 19(4): 767–77
Allen G, Barnard H, McColl R, et al. Reduced hippocampal functional connectivity in Alzheimer disease. Arch Neurol 2007 Oct; 64(10): 1482–7
Stoub TR, deToledo-Morrell L, Stebbins GT, et al. Hippocampal disconnection contributes to memory dysfunction in individuals at risk for Alzheimer’s disease. Proc Natl Acad Sci U S A 2006 Jun 27; 103(26): 10041–5
deToledo-Morrell L, Stoub TR, Wang C. Hippocampal atrophy and disconnection in incipient and mild Alzheimer’s disease. Prog Brain Res 2007; 163: 741–53
van de Pol LA, van der Flier WM, Korf ES, et al. Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology 2007 Oct 9; 69(15): 1491–7
Henneman WJ, Sluimer JD, Barnes J, et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 2009 Mar 17; 72(11): 999–1007
Maestú F, Arrazola J, Fernández A, et al. Do cognitive patterns of brain magnetic activity correlate with hippocampal atrophy in Alzheimer’s disease? J Neurol Neurosurg Psychiatry 2003 Feb; 74(2): 208–12
Fjell AM, Amlien IK, Westlye LT, et al. Mini-mental state examination is sensitive to brain atrophy in Alzheimer’s disease. Dement Geriatr Cogn Disord 2009; 28(3): 252–8
Petersen RC. Early diagnosis of Alzheimer’s disease: is MCI too late? Curr Alzheimer Res 2009 Aug; 6(4): 324–30
Celsis P. Age-related cognitive decline, mild cognitive impairment or preclinical Alzheimer’s disease? Ann Med 2000 Feb; 32(1): 6–14
den Heijer T, Launer LJ, Prins ND, et al. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology 2005 Jan 25; 64(2): 263–7
Obisesan TO. Hypertension and cognitive function. Clin Geriatr Med 2009 May; 25(2): 259–88
Korf ES, Scheltens P, Barkhof F, et al. Blood pressure, white matter lesions and medial temporal lobe atrophy: closing the gap between vascular pathology and Alzheimer’s disease? Dement Geriatr Cogn Disord 2005; 20(6): 331–7
Etgen T, Brönner M, Sander D, et al. Somatic factors in cognitive impairment. Fortschr Neurol Psychiatr 2009 Feb; 77(2): 72–82
Dai W, Lopez OL, Carmichael OT, et al. Abnormal regional cerebral blood flow in cognitively normal elderly subjects with hypertension. Stroke 2008 Feb; 39(2): 349–54
Dhikav V, Verma M, Anand K. Is hypertension a predictor of hippocampal atrophy in Alzheimer’s disease? Int Psychogeriatr 2009 Aug; 21(4): 795–6
Skoog I, Gustafson D. Update on hypertension and Alzheimer’s disease. Neurol Res 2006 Sep; 28(6): 605–11
Korf ES, White LR, Scheltens P, et al. Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension 2004 Jul; 44(1): 29–34
Skoog I, Gustafson D. Hypertension, hypertensionclustering factors and Alzheimer’s disease. Neurol Res 2003 Sep; 25(6): 675–80
Skoog I. Vascular aspects in Alzheimer’s disease. J Neural Transm Suppl 2000; 59: 37–43
De Leeuw FE, Barkhof F, Scheltens P. Alzheimer’s disease: one clinical syndrome, two radiological expressions — a study on blood pressure. J Neurol Neurosurg Psychiatry 2004 Sep; 75(9): 1270–4
Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch Neurol 2009 Oct; 66(10): 1210–5
Korf ES, van Straaten EC, de Leeuw FE, et al. Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. Diabet Med 2007 Feb; 24(2): 166–71
Fournier A, Oprisiu-Fournier R, Serot JM, et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother 2009 Sep; 9(9): 1413–31
de Leeuw FE, Barkhof F, Scheltens P. Progression of cerebral white matter lesions in Alzheimer’s disease: a new window for therapy? J Neurol Neurosurg Psychiatry 2005 Sep; 76(9): 1286–8
Aszalós Z. Cerebral complications of diabetes mellitus. Orv Hetil 2007 Dec 16; 148(50): 2371–6
de la Monte SM, Wands JR. Alzheimer’s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2008 Nov; 2(6): 1101–13
Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer’s disease: review and hypothesis. Neurobiol Aging 2006 Feb; 27(2): 190–8
Helzner EP, Luchsinger JA, Scarmeas N, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 2009 Mar; 66(3): 343–8
de la Monte SM, Wands JR. Review of insulin and insulinlike growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis 2005 Feb; 7(1): 45–61
Profenno LA, Faraone SV. Diabetes and overweight associate with non-APOE4 genotype in an Alzheimer’s disease population. Am J Med Genet B Neuropsychiatr Genet 2008 Sep 5; 147B(6): 822–9
Burns JM, Donnelly JE, Anderson HS, et al. Peripheral insulin and brain structure in early Alzheimer disease. Neurology 2007 Sep 11; 69(11): 1094–104
den Heijer T, Vermeer SE, van Dijk EJ, et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003 Dec; 46(12): 1604–10
Beeri MS, Silverman JM, Davis KL, et al. Type 2 diabetes is negatively associated with Alzheimer’s disease neuropathology. J Gerontol A Biol Sci Med Sci 2005 Apr; 60(4): 471–5
Sjögren M, Blennow K. The link between cholesterol and Alzheimer’s disease. World J Biol Psychiatry 2005; 6(2): 85–97
Wolf H, Hensel A, Arendt T, et al. Serum lipids and hippocampal volume: the link to Alzheimer’s disease? Ann Neurol 2004 Nov; 56(5): 745–8
Xiong H, Callaghan D, Jones A, et al. Cholesterol retention in Alzheimer’s brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol Dis 2008 Mar; 29(3): 422–37
Stampfer MJ. Cardiovascular disease and Alzheimer’s disease: common links. J Intern Med 2006 Sep; 260(3): 211–23
Mori E, Lee K, Yasuda M, et al. Accelerated hippocampal atrophy in Alzheimer’s disease with apolipoprotein E epsilon4 allele. Ann Neurol 2002 Feb; 51(2): 209–14
Stozická Z, Zilka N, Novák M. Risk and protective factors for sporadic Alzheimer’s disease. Acta Virol 2007; 51(4): 205–22
Wolk DA, Dickerson BC, Alzheimer’s Disease Neuroimaging Initiative. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer’s disease. Proc Natl Acad Sci U S A 2010 Jun 1; 107(22): 10256–61
Sasaki M, Kodama C, Hidaka S, et al. Prevalence of four subtypes of mild cognitive impairment and APOE in a Japanese community. Int J Geriatr Psychiatry 2009 Oct; 24(10): 1119–26
Wolozin B, Bednar MM. Interventions for heart disease and their effects on Alzheimer’s disease. Neurol Res 2006 Sep; 28(6): 630–6
Caballero J, Nahata M. Do statins slow down Alzheimer’s disease? A review. J Clin Pharm Ther 2004 Jun; 29(3): 209–13
Whitfield JF. Can statins put the brakes on Alzheimer’s disease? Expert Opin Investig Drugs 2006 Dec; 15(12): 1479–85
Mendez MF, Catanzaro P, Doss RC, et al. Seizures in Alzheimer’s disease: clinicopathologic study. J Geriatr Psychiatry Neurol 1994 Oct–Dec; 7(4): 230–3
Scarmeas N, Honig LS, Choi H, et al. Seizures in Alzheimer disease: who, when, and how common? Arch Neurol 2009 Aug; 66(8): 992–7
Amatniek JC, Hauser WA, DelCastillo-Castaneda C, et al. Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia 2006 May; 47(5): 867–72
Pearlson GD, Harris GJ, Powers RE, et al. Quantitative changes in mesial temporal volume, regional cerebral blood flow, and cognition in Alzheimer’s disease. Arch Gen Psychiatry 1992 May; 49(5): 402–8
Sheline YI, Wang PW, Gado MH, et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 1996 Apr 30; 93(9): 3908–13
Larner AJ. Epileptic Seizures in AD Patients. Neuromolecular Med 2010; 12(1): 71–7
Sousa N, Almeida OF. Corticosteroids: sculptors of the hippocampal formation. Rev Neurosci 2002; 13(1): 59–84
Sousa N, Cerqueira JJ, Almeida OF. Corticosteroid receptors and neuroplasticity. Brain Res Rev 2008 Mar; 57(2): 561–70
Huang CW, Lui CC, Chang WN, et al. Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer’s disease. J Clin Neurosci 2009 Oct; 16(10): 1283–6
Sheline YI. Hippocampal atrophy in major depression: a result of depression-induced neurotoxicity? Mol Psychiatry 1996 Sep; 1(4): 298–9
Luo L, Tan RX. Fluoxetine inhibits dendrite atrophy of hippocampal neurons by decreasing nitric oxide synthase expression in rat depression model. Acta Pharmacol Sin 2001 Oct; 22(10): 865–70
Bierman EJ, Comijs HC, Jonker C, et al. The effect of anxiety and depression on decline of memory function in Alzheimer’s disease. Int Psychogeriatr 2009 Dec; 21(6): 1142–7
Panza F, D’Introno A, Colacicco AM, et al. Temporal relationship between depressive symptoms and cognitive impairment: the Italian Longitudinal Study on Aging. J Alzheimers Dis 2009; 17(4): 899–911
Dhikav V, Anand KS. Glucocorticoids may initiate Alzheimer’s disease: a potential therapeutic role for mifepristone (RU-486). Med Hypotheses 2007; 68(5): 1088–92
Cendes F. Progressive hippocampal and extrahippocampal atrophy in drug resistant epilepsy. Curr Opin Neurol 2005 Apr; 18(2): 173–7
Sapolsky RM, Uno H, Rebert CS, et al. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci 1990 Sep; 10(9): 2897–902
Sapolsky RM. Potential behavioral modification of glucocorticoid damage to the hippocampus. Behav Brain Res 1993 Nov 30; 57(2): 175–82
Lupien SJ, de Leon M, de Santi S, et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci 1998 May; 1(1): 69–73
Hyman BT, Van Hoesen GW, Damasio AR, et al. Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science 1984 Sep 14; 225(4667): 1168–70
De Lacoste MC, White 3rd CL. The role of cortical connectivity in Alzheimer’s disease pathogenesis: a review and model system. Neurobiol Aging 1993; 14(1): 1–16
Welsh KA, Butters N, Hughes JP, et al. Detection and staging of dementia in Alzheimer’s disease: use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer’s Disease. Arch Neurol 1992 May; 49(5): 448–52
Fox NC, Freeborough PA, Rossor MN. Visualisation and quantification of rates of atrophy in Alzheimer’s disease. Lancet 1996 Jul 13; 348(9020): 94–7
Schott JM, Fox NC, Frost C, et al. Assessing the onset of structural change in familial Alzheimer’s disease. Ann Neurol 2003 Feb; 53(2): 181–8
Jack Jr CR, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004 Feb 24; 62(4): 591–600
Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer’s disease. Nat Med 2004; 10: S34–41 doi: 10.1038/nrn1433
De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001 Jul–Aug; 22(4): 529–39
Bourgeat P, Chételat G, Villemagne VL, et al., AIBL Research Group. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010 Jan 12; 74(2): 121–7
Michaelis ML. Drugs targeting Alzheimer’s disease: some things old and some things new. J Pharmacol Exp Ther 2003 Mar; 304(3): 897–904
Hashimoto M, Kazui H, Matsumoto K, et al. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer’s disease? Am J Psychiatry 2005 Apr; 162(4): 676–82
Kamiyama K, Wada A, Sugihara M, et al. Potential hippocampal region atrophy in diabetes mellitus type 2: a voxel-based morphometry VSRAD study. Jpn J Radiol 2010 May; 28(4): 266–72
Rasgon NL, Kenna HA, Wroolie TE, et al. Insulin resistance and hippocampal volume in women at risk for Alzheimer’s disease. Neurobiol Aging. Epub 2009 Dec 24; doi:10.1016/j.neurobiolaging.2009.12.005
Sato T, Hanyu H, Hirao K, et al. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging. Epub 2009 Nov 16; doi:10.1016/j.neurobiolaging. 2009.10.009
Plastino M, Fava A, Pirritano D, et al. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci 2010 Jan 15; 288(1–2): 112–6
Deschaintre Y, Richard F, Leys D, et al. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 2009 Sep 1; 73(9): 674–80
Fox NC, Crum WR, Scahill RI, et al. Imaging of onset and progression of Alzheimer’s disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001 Jul 21; 358(9277): 201–5
Ringman JM, Medina LD, Rodriguez-Agudelo Y, et al. Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer’s disease. Curr Alzheimer Res 2009 Aug; 6(4): 341–6
Risacher SL, Saykin AJ, West JD, et al., Alzheimer’s Disease Neuroimaging Initiative (ADNI). Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 2009 Aug; 6(4): 347–61
Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature 2006 Oct 19; 443(7113): 768–73
Dhikav V, Anand KS. Is hippocampal atrophy a future drug target? Med Hypotheses 2007; 68(6): 1300–6
Rountree SD, Chan W, Pavlik VN, et al. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease [abstract]. Alzheimers Res Ther 2009 Oct 21; 1(2): 7
Lynch G. Memory enhancement: the search for mechanism-based drugs. Nat Neurosci 2002 Nov; 5 Suppl.: 1035–8
Frisoni GB, Fox NC, Jack Jr CR, et al. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010 Feb; 6(2): 67–77
Ferreira LK, Diniz BS, Forlenza OV, et al. Neurostructural predictors of Alzheimer’s disease: a meta-analysis of VBM studies. Neurobiol Aging. Epub 2010; doi:10.1016/j.neurobiolaging.2009.11.008
DeCarolis NA, Eisch AJ. Hippocampal neurogenesis as a target for the treatment of mental illness: a critical evaluation. Neuropharmacology 2010 May; 58(6): 884–93
Sluimer JD, van der Flier WM, Karas GB, et al. Accelerating regional atrophy rates in the progression from normal aging to Alzheimer’s disease. Eur Radiol 2009 Dec; 19(12): 2826–33
Wang PN, Liu HC, Lirng JF, et al. Accelerated hippocampal atrophy rates in stable and progressive amnestic mild cognitive impairment. Psychiatry Res 2009 Mar 31; 171(3): 221–31
Valenzuela MJ, Sachdev P, Wen W, et al. Lifespan mental activity predicts diminished rate of hippocampal atrophy [abstract]. PLoS One 2008 Jul 9; 3(7): e2598
Honea RA, Thomas GP, Harsha A, et al. Cardiorespiratory fitness and preserved medial temporal lobe volume in Alzheimer disease. Alzheimer Dis Assoc Disord 2009 Jul–Sep; 23(3): 188–97
Redila VA, Olson AK, Swann SE, et al. Hippocampal cell proliferation is reduced following prenatal ethanol exposure but can be rescued with voluntary exercise. Hippocampus 2006; 16(3): 305–11
Hüll M, Berger M, Heneka M. Disease-modifying therapies in Alzheimer’s disease: how far have we come? Drugs 2006; 66(16): 2075–93
Busse A, Angermeyer MC, Riedel-Heller SG. Progression of mild cognitive impairment to dementia: a challenge to current thinking. Br J Psychiatry 2006 Nov; 189: 399–404
Miller DB, O’Callaghan JP. Aging, stress and the hippocampus. Ageing Res Rev 2005 May; 4(2): 123–40
Peters R. Ageing and the brain. Postgrad Med J 2006 Feb; 82(964): 84–8
Neugroschl J, Sano M. An update on treatment and prevention strategies for Alzheimer’s disease. Curr Neurol Neurosci Rep 2009 Sep; 9(5): 368–76
Acknowledgements
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dhikav, V., Anand, K. Potential Predictors of Hippocampal Atrophy in Alzheimer’s Disease. Drugs Aging 28, 1–11 (2011). https://doi.org/10.2165/11586390-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11586390-000000000-00000